We focus on promising drug and vaccine candidates for diseases of poverty that can benefit significantly from the application of emerging and advanced delivery and manufacturing technologies.

Such technologies can often make the difference between a drug or vaccine candidate whose inherent instability or cost will never allow its practical development, versus a successful medicine that can meet the restrictive criteria – low cost of manufacturing, oral or needle-less dosing, lack of refrigeration – necessary for real impact in the countries where the need is greatest.

We believe that the best solutions to the global challenge come from broad and transparent collaboration amongst very diverse groups, including the substantial inclusion of emerging research and capabilities in the developing world.

MEND consists of two related but independent divisions created to achieve its goal:

MEND Biotechnology Development    MEND Innovation & Translation Alliance Management

Learn More